ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
| Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
|---|---|---|---|---|
| Targeting the immunosuppressive effects of Myc-hyperactivation in high-risk osteosarcoma | Emory University / Jason Yustein, MD/PhD | Innovation Grants | 2024 | Georgia |
| Development of allogeneic off-the-shelf gamma delta T cell product for pediatric AML | Baylor College of Medicine / Norihiro Watanabe, PhD | Innovation Grants | 2024 | Texas |
| The role of reactive gliosis in response to Immunotherapy in Diffuse Midline Glioma | University of Florida / Christina von Roemeling, PhD | Innovation Grants | 2024 | Florida |
| Targeting and imaging immunometabolic vulnerabilities in diffuse midline glioma | The Regents of the University of California San Francisco / Pavithra Viswanath, PhD | Innovation Grants | 2024 | California |
| DMG: From SWI/SNF’s role in cholesterol biosynthesis to new therapeutic opportunities | Board of Trustees of the Leland Stanford Junior University / Capucine Van Rechem, PhD | Innovation Grants | 2024 | California |
| RAF Dimer Inhibitor Treatment in Pediatric Acute Myeloid Leukemia | The Regents of the University of California San Francisco / Kevin Shannon, MD | Innovation Grants | 2024 | California |
| The role of tissue kallikrein 1 in hematopoietic stem cell transplant-associated thrombotic microangiopathy | Baylor College of Medicine / Sarah Sartain, MD | Innovation Grants | 2024 | Texas |
| Unraveling the Mechanisms of Inherited Predisposition to Childhood Leukemia | Boston Children’s Hospital / Vijay Sankaran, MD/PhD | Innovation Grants | 2024 | Massachusetts |
| Illuminating Choroid Plexus Carcinoma Vascularization in Real Time | Boston Children’s Hospital / Maria Lehtinen, PhD | Innovation Grants | 2024 | Massachusetts |
| Targeting of a putative unresolved wound healing process in childhood ependymoma | University of Colorado Denver / Nicholas Foreman, MD | Innovation Grants | 2024 | Colorado |
| Pathological Condensates and Transcription Dysregulation in Rhabdomyosarcoma at Single-Molecule Resolution | California Institute of Technology / Shasha Chong, PhD | Innovation Grants | 2024 | California |
| Development of CAR-T therapy for Ewing sarcoma using zebrafish in vivo models | Children’s Hospital Los Angeles / James Amatruda, MD/PhD | Innovation Grants | 2024 | California |
| Development of CAR-T therapy for Ewing sarcoma using zebrafish in vivo models | Children’s Hospital Los Angeles / James Amatruda, MD/PhD | Innovation Grants | 2024 | California |
| Direct targeting of oncoprotein assembly using mimetic peptide interference | Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD | Innovation Grants | 2024 | New York |
| Structure-guided de novo design of molecules that selectively target EWS-FLI1 | University of Texas Health Science Center at San Antonio / David Libich, PhD | Innovation Grants | 2023 | Texas |
| Inducing Neuroblastoma Differentiation In Vivo | University of Alabama at Birmingham / Ankur Saxena, PhD | Innovation Grants | 2023 | Alabama |
| The Impact of the Intestinal Microbiome on Sarcoma Metastasis | Albert Einstein College of Medicine / David Loeb, MD, PhD | Innovation Grants | 2023 | New York |
| Ectopic Neuroligin Signaling in Pediatric Glioblastoma | University of Utah / Alex Shcheglovitov, PhD | Innovation Grants | 2023 | Utah |
| Mechanisms to Redirect Tumor Associated Macrophages to Target Retinoblastoma Cells | The Regents of the University of Minnesota / Timothy Hallstrom, PhD | Innovation Grants | 2023 | Minnesota |
| Development of RADARS-based Therapy to Treat Fusion Molecule Driven Pediatric Malignancies | Boston Children’s Hospital / Alan B. Cantor, MD, PhD | Innovation Grants | 2023 | Massachusetts |
| Stapled Oncolytic Peptides for Treatment-Resistant Pediatric Leukemias | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD | Innovation Grants | 2023 | Massachusetts |
| Targeting Chromatin Remodeling Complexes for Rhabdomyosarcoma (RMS) Therapy | Dana-Farber Cancer Institute / Jun Qi, PhD | Innovation Grants | 2023 | Massachusetts |
| CDK12 Links Radiation Response to PARPi Sensitivity in Pediatric Glioma | University of Colorado Denver_ Anschutz Medical Campus / Nathan Dahl, MD | Innovation Grants | 2023 | Colorado |
| Desmoplastic Small Round Cell Tumors: Investigation of its Pathogenesis and Development of Novel Therapies | Memorial Sloan-Kettering Cancer Center / Andrea Ventura, MD, PhD | Innovation Grants | 2023 | New York |
| Targeting Neurons in the Osteosarcoma Microenvironment with Non-Opioid Analgesic Lipid Nanoparticles | The Johns Hopkins University School of Medicine / Aaron James, MD, PhD | Innovation Grants | 2023 | Maryland |
| Novel Resilience Genes Required for Cerebellum Development and Medulloblastoma Survival | University of California San Francisco / Stephen Fancy, PhD, DVM | Innovation Grants | 2023 | California |
| In Situ CD19.CAR-T Generation Using TRIDENT System for Pediatric B Cell Malignancies | Baylor College of Medicine / Masataka Suzuki, PhD | Innovation Grants | 2023 | Texas |
| Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma | Dana-Farber Cancer Institute / Rani George, MD, PhD | Innovation Grants | 2022 | Massachusetts |
| Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | Maryland |
| Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia | Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD | Innovation Grants | 2022 | New York |
| Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy | University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD | Innovation Grants | 2022 | Wisconsin |
| Molecular circuitry of fibrolamellar carcinoma | Massachusetts General Hospital / Nabeel Bardeesy, PhD | Innovation Grants | 2022 | Massachusetts |
| Developmental origins of leukemia in Down Syndrome | University of Rochester / James Palis, MD & Laurie Steiner, MD | Innovation Grants | 2022 | New York |
| Blocking the Evil Messenger in MYCN-driven High-risk Neuroblastoma | Boston University / Hui Feng, Md, PhD | Innovation Grants | 2022 | Massachusetts |
| Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma | University of Massachusetts Chan Medical School / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD | Innovation Grants | 2022 | Massachusetts |
| Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma | University of Massachusetts Amherst / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD | Innovation Grants | 2022 | Massachusetts |
| Impact of STAG2 loss on DNA Damage and Immunobiology in Ewing sarcoma | University of Pittsburgh / Kelly Bailey, MD, PhD | Innovation Grants | 2022 | Pennsylvania |
| Isoform-specific TNC-redirected T cell Therapy for DIPG | St. Jude Children’s Research Hospital / Stephen Gottschalk, MD and Giedre Krenciute, PhD | Innovation Grants | 2022 | Tennessee |
| Novel targeting approach for pediatric B-cell malignancies | Thomas Jefferson University / Christine Eischen, PhD | Innovation Grants | 2021 | Pennsylvania |
| Targeting EZHIP as a therapeutic strategy for infantile ependymomas | University of Wisconsin - Madison / Peter Lewis, PhD | Innovation Grants | 2021 | Wisconsin |
| Hematopoietic stem cell function in familial platelet disorder therapy | University of Massachusetts Medical School / Lucio Castilla, PhD | Innovation Grants | 2021 | Massachusetts |
| Unraveling metabolic dependencies in childhood supratentorial ependymomas. | Regents of the University of Michigan / Sriram Venneti, MD/PhD | Innovation Grants | 2021 | Michigan |
| Role of H3.3-G34R mutation in pediatric high-grade glioma | University of Texas M.D. Anderson Cancer Center / Jian Hu, PhD | Innovation Grants | 2021 | Texas |
| Phosphopeptides as shared targets for donor derived T cell therapy of AML | Memorial Sloan-Kettering Cancer Center / Richard O'Reilly, MD | Innovation Grants | 2021 | New York |
| A leukemia organoid platform for dissection and targeting of tumor-niche interactions | Columbia Institute for Cancer Genetics / Adolfo Ferrando, MD/PhD | Innovation Grants | 2021 | New York |
| Targeting tumor associated macrophages in metastatic Ewing sarcoma (ES) | New York Medical College / Mitchell Cairo, MD | Innovation Grants | 2021 | New York |
| Loss of ER-mitochondria contacts drives therapy resistance in neuroblastoma | Children’s Hospital of Philadelphia / Michael Hogarty, MD | Innovation Grants | 2021 | Pennsylvania |
| Choline Kinase and Alkylating Agent Resistance in Refractory Childhood Leukemias | Boston Children’s Hospital / Alejandro Gutierrez, MD | Innovation Grants | 2021 | Massachusetts |
| In-vivo characterization of MYCN-driven immunosuppression | University of California San Francisco / William Weiss, MD/PhD | Innovation Grants | 2021 | California |
| Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma | Columbia University / Darrell Yamashiro, MD/PhD | Innovation Grants | 2021 | New York |
| The use of hematopoietic stem and progenitor cells to reverse treatment resistance to PD-1 blockade | University of Florida / Catherine Flores, PhD | Innovation Grants | 2019 | Florida |
| Identify Novel Druggable Targets to Treat Philadelphia chromosome-like B-Acute Lymphoblastic Leukemia | Children’s Hospital of Philadelphia / Wei Tong, PhD | Innovation Grants | 2019 | Pennsylvania |
| Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy | Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD | Innovation Grants | 2019 | Ohio |
| Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies | Emory University / Christopher Porter, MD | Innovation Grants | 2019 | Georgia |
| The anti-tumor immune microenvironment in the Sonic Hedgehog subclass of medulloblastoma | Emory University / Anna Kenney, PhD | Innovation Grants | 2019 | Georgia |
| Therapeutic Targeting of the Disrupted Metabolic State in DIPG | University of Michigan / Costas Lyssiotis, PhD & Sriram Venneti, MD/PhD | Innovation Grants | 2019 | Michigan |
| Norepinephrine Transporter-Targeted Pharmacotherapy of Aggressive Neuroblastoma | Children’s Hospital of Philadelphia / Michael Chorny, PhD | Innovation Grants | 2019 | Pennsylvania |
| Targeting microenvironment-induced TGFB signaling to overcome drug resistance in acute lymphoblastic leukemia | St. Jude Children’s Research Hospital / Charles Mullighan, MD | Innovation Grants | 2019 | Tennessee |
| Novel Therapy of Heterogeneous B-cell Acute Lymphocytic Leukemia by Targeting Convergent Oncogenic Mediators STATs | University of Alberta / Hasan Uludag, PhD | Innovation Grants | 2019 | Alberta |
| Pediatric Osteosarcoma: Identifying the elusive molecular signature and its relationship to this disease | St. Jude Children’s Research Hospital / Linda Hendershot, PhD | Innovation Grants | 2019 | Tennessee |
| Saturating CRISPR gene body scans in MLL-rearranged leukemia | Beckman Research Institute of City of Hope / Chun-Wei Chen, PhD | Innovation Grants | 2019 | California |
| Role of the macro lncRNA KCNQ1OT1 in embryonal rhabdomyosarcoma tumorigenesis | Duke University / Corinne Linardic, MD/PhD | Innovation Grants | 2019 | North Carolina |
| Predicting and Overcoming Resistance to Immunotherapy in Pediatric High-Grade Glioma | Ann & Robert H. Lurie Children’s Hospital of Chicago / Oren Becher, MD & Robert Wechsler-Reya, PhD | Innovation Grants | 2019 | Illinois |
| Selectively targeting EP300 with small molecules for neuroblastoma (NB) therapy | Dana-Farber Cancer Institute / Jun Qi, PhD | Innovation Grants | 2019 | Massachusetts |
| Epigenetic regulation of genomic instability and its therapeutic implications in T-cell acute lymphoblastic leukemia | Dana-Farber Cancer Institute / Birgit Knoechel, MD/PhD | Innovation Grants | 2019 | Massachusetts |
| Targeting symmetric division in pediatric cancers | Dana-Farber Cancer Institute / Rosalind Segal, MD/PhD | Innovation Grants | 2019 | Massachusetts |
| Identifying targeted treatments for DICER1-associated sarcomas | Research Institute of the McGill University Health Centre / William Foulkes, MD/PhD & Sidong Huang, PhD | Innovation Grants | 2019 | Quebec |
| CD36-Sphingosine 1-Phosphate Axis in Osteosarcoma Progression | Medical University of South Carolina / Meenal Mehrotra, MD/PhD | Innovation Grants | 2019 | South Carolina |
| Developing drugs to treat NT5C2 mediated resistance in pediatric ALL | New York University School of Medicine / William Carroll, MD | Innovation Grants | 2019 | New York |
| Physical Properties of Drug-Resistant Leukemia Cells | Children’s Hospital Los Angeles / Yong-mi Kim, MD/PhD | Innovation Grants | 2018 | California |
| Targeting the ALT Pathway to Induce Synthetic Lethality and Treat Poor Outcome Pediatric Tumors | University of California, Davis / Wolf-Dietrich Heyer, PhD | Innovation Grants | 2018 | California |
| Alternative Splicing Driven by MYCN Activates RAS-MAPK in Neuroblastoma | University of California San Francisco / William Weiss, MD/PhD | Innovation Grants | 2018 | California |
| RNA-ECS to Quantify Rare Clonal RNA Species at Diagnosis, Remission and Relapse from the COG AAML1031 Study | Washington University / Todd Druley, MD/PhD | Innovation Grants | 2018 | Missouri |
| Targeting Glutamine Addiction in Diffuse Intrinsic Pontine Gliomas (DIPGs) | University of Michigan / Sriram Venneti, MD/PhD | Innovation Grants | 2018 | Michigan |
| RNA Methylation in Metabolically Disrupted Pediatric Cancers | University of Texas Health Science Center at San Antonio / Patricia Dahia, MD/PhD | Innovation Grants | 2018 | Texas |
| Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia? | University of Utah / Michael Deininger, MD/PhD | Innovation Grants | 2018 | Utah |
| Targeting Oncogenic RAS in Pediatric Leukemia | Dana-Farber Cancer Institute / Loren Walensky, MD/PhD | Innovation Grants | 2018 | Massachusetts |
| Identifying New Therapeutic Targets in Fibrolamellar Hepatocellular Carcinoma | Stanford University / Julien Sage, PhD | Innovation Grants | 2018 | California |
| Modeling and Therapeutic Targeting of p21-Activated Kinase Members in High-Risk Rhabdomyosarcoma | Baylor College of Medicine / Jason Yustein, MD/PhD | Innovation Grants | 2018 | Texas |
| Molecular Landscape for Targeted Therapy in Retinoblastoma | University of Miami / James Harbour, MD | Innovation Grants | 2018 | Florida |
| Targeting KDM6B in Pediatric Leukemia | Washington University / Grant A. Challen, PhD | Innovation Grants | 2018 | Missouri |
| Energy Balance Strategies for Decreasing Chemotherapy-Induced Cardiotoxicity | University of Texas M.D. Anderson Cancer Center / Eugenie Kleinerman, MD | Innovation Grants | 2018 | Texas |
| Circulating Repetitive Element RNAs as an Osteosarcoma Marker | Children’s Hospital Los Angeles / David Cobrinik, MD/PhD | Innovation Grants | 2018 | California |
| Nuclear Receptor Tyrosine Kinases Mediating Chromatin Remodeling & Checkpoint Adaption | Children’s Cancer Therapy Development Institute / Charles Keller, MD | Innovation Grants | 2018 | Oregon |
| Olfactory Ensheathing Cells for Pediatric Glioma Gene/Cell Therapy | Massachusetts General Hospital / Bakhos Tannous, PhD | Innovation Grants | 2018 | Massachusetts |
| Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas | University of Manitoba / Tamra Werbowetski-Ogilvie, PhD | Innovation Grants | 2017 | Manitoba |
| Alternative Splicing in the Pathogenesis of Acute Lymphoblastic Leukemia | Children’s Hospital of Philadelphia / Andrei Thomas-Tikhonenko, PhD | Innovation Grants | 2017 | Pennsylvania |
| De-escalation of Radiotherapy for Medulloblastoma by a Novel DNA Damage Checkpoint Inhibitor | Feinstein Institute for Medical Research - North Shore / Marc Symons, PhD | Innovation Grants | 2017 | New York |
| 3-D Printed Self-fitting Shape Memory Bone Grafts for Smart Pediatric Skeletal Reconstruction | University of Massachusetts Medical School / Jie Song, PhD | Innovation Grants | 2017 | Massachusetts |
| Targeted Degradation of Proliferative Transcription Factors in Pediatric Cancers | University of California at Santa Cruz / Seth Rubin, PhD | Innovation Grants | 2017 | California |
| Mechanisms of OTX2 Mediated Chromatin Regulation in Medulloblastoma | Massachusetts General Hospital / Miguel Rivera, MD | Innovation Grants | 2017 | Massachusetts |
| Novel Approaches for Epigenetic Therapy for Relapsed Acute Lymphoblastic Leukemia | The Johns Hopkins University School of Medicine / Linda Resar, MD & Andrei Thomas-Tikhonenko, PhD | Innovation Grants | 2017 | Maryland |
| Establishing the Function of Novel MicroRNAs Associated with Resistance and Relapse in Pediatric AML | Fred Hutchinson Cancer Research Center / Vivian Oehler, MD & Soheil Meshinchi, MD/PhD | Innovation Grants | 2017 | Washington |
| Targeting Childhood Brain Cancer in a Dish to Catalyze New Therapies | University of California, Davis Medical Center / Paul Knoepfler, PhD | Innovation Grants | 2017 | California |
| Role of Protocadherin-9 in Enabling Leukemia Cell Colonization of the CNS | National Jewish Health / Jordan Jacobelli, PhD | Innovation Grants | 2017 | Colorado |
| Development of Mithramycin Analogs for Ewing sarcoma | Van Andel Research Institute / Patrick Grohar, MD/PhD | Innovation Grants | 2017 | Michigan |
| Targeting Metabolic Vulnerabilities in ETP-ALL | Columbia University / Adolfo A. Ferrando, MD/PhD | Innovation Grants | 2017 | New York |
| Defining the Cell Surface Landscape of Diagnostic and Relapsed Neuroblastoma: Immunotherapeutic Target Identification | Children’s Hospital of Philadelphia / Sharon Diskin, PhD | Innovation Grants | 2017 | Pennsylvania |
| Predictive Modeling of MDS Disease Progression From Inherited Bone Marrow Failure Syndrome Using Novel Branching Process and Next Generation Sequencing to Improve Patient-Specific Survival | Cleveland Clinic Foundation / Seth Corey, MD & Marek Kimmel, PhD | Innovation Grants | 2017 | Ohio |
| Genome-Wide 5hmC Profiling of Neuroblastoma Tumors and Patient Cell-Free DNA | University of Chicago / Susan Cohn, MD & Chuan He PhD | Innovation Grants | 2017 | Illinois |
| Targeting Pediatric Brain Tumors Using PTPmu Nanochains with Radiofrequency-Releasable Therapeutics | Case Western Reserve University / Susann Brady-Kalnay, PhD & Efstathios Karathanasis, PhD | Innovation Grants | 2017 | Ohio |
| Development of Nanoparticle-Encapsulated Chemo/Radio-Sensitizers for Intrathecal Delivery | Yale School of Medicine / Ranjit S. Bindra, MD/PhD & Mark Saltzman, PhD | Innovation Grants | 2017 | Connecticut |
| Targeting BRD9 in Sarcoma | Dana-Farber Cancer Institute / Scott Armstrong, MD/PhD | Innovation Grants | 2017 | Massachusetts |
| Long Non-Coding RNAs as Novel Biomarkers and Therapeutic Targets in Pediatric Leukemia | New York University School of Medicine / Iannis Aifantis, PhD | Innovation Grants | 2017 | New York |
| Detection of Circulating Tumor DNA in Pediatric Sarcomas | The Regents of the University of California San Francisco / Alejandro Sweet-Cordero, MD & Maximillian Diehn, MD/PhD (Stanford University) | Innovation Grants | 2016 | California |
| Improving Immune-Mediated Oncolytic Viral Therapy: Engineering Tumor Vaccine Elements into the Virus | Research Institute at Nationwide Children's Hospital / Kevin Cassady, MD & Christopher Walker, PhD | Innovation Grants | 2016 | Ohio |
| Developing and Distributing a Pediatric Spinal Cord High-grade Glioma Model | Stanford University / Michelle Monje, MD/PhD | Innovation Grants | 2016 | California |
| Preclinical Testing of Candidate Therapeutics in a Pediatric Spinal Cord High-grade Glioma Model | Stanford University / Michelle Monje, MD/PhD | Innovation Grants | 2016 | California |
| Enhancing Pediatric Sarcoma Immunotherapy by Drug Induced Expression of Tumor-Specific Cryptic Neoantigens | University of Minnesota / David Largaespada, PhD | Innovation Grants | 2016 | Minnesota |
| Image Guided Diffuse Intrinsic Pontine Glioma Drug Delivery and Design | Weill Cornell Medical College / Mark Souweidane, MD & Richard Ting, PhD | Innovation Grants | 2016 | New York |
| Redefining the Cellular Architecture of Diffuse Intrinsic Pontine Glioma through Large-Scale Single-cell RNA-seq Analyses | Massachusetts General Hospital / Mario Suva, MD/PhD | Innovation Grants | 2016 | Massachusetts |
| Circulating Exosomes as Biomarkers of Medulloblastoma Progression, Metastasis, and Recurrence | Weill Cornell Medical College / David Lyden, MD/PhD & Parveen Raju, MD/PhD | Innovation Grants | 2016 | New York |
| Targeted Inhibition of Lin28/let-7 Binding to Treat Pediatric Malignancy | Boston Children’s Hospital / George Q. Daley, MD/PhD | Innovation Grants | 2016 | Massachusetts |
| GeneEditing in T cell Leukemia to Promote Immunomodulatory Forms of Cell Death | Boston Children’s Hospital / Dr. Ben Croker, PhD | Innovation Grants | 2016 | Massachusetts |
| Modeling Pediatric Spinal Gliomas Using Murine Spinal Neural Stem Cells | The Johns Hopkins University School of Medicine / Charles Eberhart, MD/PhD & Eric Raabe MD/PhD | Innovation Grants | 2016 | Maryland |
| DICER1-Driven Cancers: Models, Mechanisms and Therapies | University of Texas Southwestern Medical Center at Dallas / James Amatruda, MD/PhD | Innovation Grants | 2016 | Texas |
| Targeting Microenvironmental Support of Acute Lymphoblastic Leukemia | University of Rochester / Craig Mullen, MD/PhD | Innovation Grants | 2016 | New York |
| Development of an anti-KIR3DL1 Antibody to Promote Innate Immunity Against Neuroblastoma | Memorial Sloan-Kettering Cancer Center / Katherine Hsu, MD/PhD & Nai-Kong Cheung, MD/PhD | Innovation Grants | 2016 | New York |
| Enhancing Immunotherapy of Neuroblastoma | The Regents of the University of California, San Diego / Alice Yu, MD/PhD & Mitchell Diccianni, PhD | Innovation Grants | 2016 | California |
| MYC as a Driver and Anti-Cancer Target in Malignant Rhabdoid Tumors | Vanderbilt University Medical Center / William Tansey, PhD | Innovation Grants | 2016 | Tennessee |
| HOX Genes As Developmental Regulators Of Sarcomagenesis | University of Michigan / Elizabeth Lawlor, MD/PhD & Deneen Wellik, PhD | Innovation Grants | 2016 | Michigan |
| Targeted Combination Therapy to Sensitize High-Risk Acute Lymphoblastic Leukemia to Methotrexate via Restoration of Ikaros Tumor Suppression | The Pennsylvania State University / Sinisa Dovat, MD/PhD & Chunhua Song, MD/PhD | Innovation Grants | 2016 | Pennsylvania |
| Targeting the Function of Ezrin in Rhabdomyosarcoma | The Cleveland Clinic Foundation / Neetu Gupta, PhD & Peter Anderson, MD | Innovation Grants | 2016 | Ohio |
| CD47-blocking Oncolytic Vaccinia Viruses as Biotherapeutics for Pediatric Solid Tumors | St. Jude Children’s Research Hospital / Stephen Gottschalk, MD & Nino Rainusso, MD | Innovation Grants | 2016 | Tennessee |
| Pre-clinical Testing of Novel Glutamine Metabolic Inhibitors in MYC-driven Medulloblastoma | The Johns Hopkins University School of Medicine / Eric Raabe, MD/PhD & Dr. Barbara Slusher, PhD | Innovation Grants | 2016 | Maryland |
| Selective Epigenetic Regulation of Notch1 in T-cell Acute Lymphoblastic Leukemia | University of Michigan / Mark Yat-Fung Chiang, MD/PhD | Innovation Grants | 2016 | Michigan |
| Targeting MYCN-amplified Neuroblastoma Through RORalpha Activation | Baylor College of Medicine / Eveline Barbiere, MD | Innovation Grants | 2016 | Texas |
| Cure Osteosarcoma Lung Metastasis by Disrupting Tumor VCAM-1 Signaling with Macrophages | Case Western Reserve University / Alex Huang, MD, PhD | Innovation Grants | 2015 | Ohio |
| In Vivo Analysis of Early Neuroblastoma Development using Transgenic Quail | Stowers Institute for Medical Research / Paul Kulesa, PhD | Innovation Grants | 2015 | Missouri |
| Histone H3.3 Targeted Therapy for Pediatric High-grade Gliomas | University of California, Davis Medical Center / Paul Knoepfler, PhD | Innovation Grants | 2015 | California |
| Regulation of Tumor Debris Mediated Inflammation as a Therapeutic Modality in Medulloblastoma | Dana-Farber Cancer Institute / Mark Kieran, MD, PhD & Dipak Panigrahy, MD | Innovation Grants | 2015 | Massachusetts |
| Identifying Mechanisms of Glucocorticoid Resistance in Pediatric Acute Lymphoblastic | University of Massachusetts Medical School / Michelle Kelliher, PhD | Innovation Grants | 2015 | Massachusetts |
| Enhanced Drug Repurposing Screen in DSRCT Enabled by New In Vitro and In Vivo Models Based on CRISPR/Cas9 Genome Engineering | Memorial Sloan-Kettering Cancer Center / Marc Ladanyi, MD & Maria Jasin, PhD | Innovation Grants | 2015 | New York |
| High-dimensional Biochemical CyTOF Analysis of Pediatric T cell Leukemias | University of California San Francisco / Jeroen Roose, PhD | Innovation Grants | 2015 | California |
| Developing a Novel Tumor Model to Screen for New Therapies for Spinal Ependymoma | The Johns Hopkins University School of Medicine / Linda Resar, MD & Richard Schlegel, MD, PhD | Innovation Grants | 2015 | Maryland |
| Integrative Genomic and Immunogenomic Analysis of Neuroblastoma | University of California at Santa Cruz / David Haussler, PhD | Innovation Grants | 2015 | California |
| Identifying Epigenetic Mechanisms Impacting Neuroblastoma Genome Stability and Drug Response | Massachusetts General Hospital / Johnathan Whetstine, PhD | Innovation Grants | 2015 | Massachusetts |
| Optimizing Bispecific Antibody Therapy for Acute Leukemias | Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD & James Olson, MD, PhD | Innovation Grants | 2015 | Washington |
| Functional Analysis and Therapeutic Targeting of STAG2 Mutations in Ewing sarcoma | Georgetown University / Todd Waldman, MD, PhD | Innovation Grants | 2015 | District of Columbia |
| Identifying how Pre-existing Anti-Therapeutic Antibodies (PATA) are Associated with Better Outcome in a Clinical Trial of ADCC-inducing Anti-GD2 mAb | University of Wisconsin - Madison / Paul Sondel, MD, PhD | Innovation Grants | 2015 | Wisconsin |
| Antibody Targeted Natural Killer Cell-Derived Extracellular Vesicles for the Treatment of Childhood Acute Lymphoblastic Leukemia and Neuroblastoma | Children’s Hospital Los Angeles / Robert Seeger, MD & Alan Wayne, MD | Innovation Grants | 2015 | California |
| Preclinical Development of Atr Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy | University of North Carolina / Timothy Gershon, MD, PhD | Innovation Grants | 2015 | North Carolina |
| Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma | Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP) | Innovation Grants | 2015 | Virginia |
| Single Cell Analysis of Leukemia Initiation | Stanford University / Michael Cleary, MD | Innovation Grants | 2015 | California |
| Transcriptional Effectors of Activated RAS Signaling in Juvenile Myelomonocytic Leukemia | Boston Children’s Hospital / Alan Cantor, MD, PhD | Innovation Grants | 2015 | Massachusetts |
| Synergistic Differentiation Therapy in Neuroblastoma | Duke University / Gerard Blobe, M.D./Ph.D | Innovation Grants | 2015 | North Carolina |
| Enhancing Effectiveness of Immune Checkpoint Therapy in Neuroblastoma | Children’s Hospital Los Angeles / Shahab Asgharzadeh, MD | Innovation Grants | 2015 | California |
| Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma | University of Virginia, School of Medicine / John Bushweller, PhD | Innovation Grants | 2015 | Virginia |
| Characterizing Resistance Mechanisms to BET-Bromodomain Inhibition in MYC-amplified | Broad Institute / Rameen Beroukhim, MD,PhD | Innovation Grants | 2015 | Massachusetts |
| Targeting eEF2 Kinase in Neuroblastoma | University of California San Francisco / William Weiss, M.D., Ph.D. | Innovation Grants | 2014 | California |
| Modeling Juvenile Myelomonocytic Leukemia with Patient-Derived Induced Pluripotent Stem Cells | Children’s Hospital of Philadelphia / Mitchell Weiss, M.D., Ph.D. | Innovation Grants | 2014 | Pennsylvania |
| Targeting the Accomplices of MYC in MYC-driven Medulloblastoma | Sanford-Burnham Medical Research Institute / Robert Wechsler-Reya, Ph.D. | Innovation Grants | 2014 | California |
| The Tumor Suppressive Role of LNK (SH2B3) in Acute Lymphoblastic Leukemia | Children’s Hospital of Philadelphia / Wei Tong, PhD | Innovation Grants | 2014 | Pennsylvania |
| Therapies for SHH-subtype Medulloblastoma | Dana-Farber Cancer Institute / Rosalind Segal, M.D., Ph.D. | Innovation Grants | 2014 | Massachusetts |
| Targeting Tumor Suppressor MicroRNAs in Pediatric Acute Lymphoblastic Leukemia | The Johns Hopkins University School of Medicine / Linda Resar, M.D. | Innovation Grants | 2014 | Maryland |
| Trib2 in the Pathogenesis of T-ALL | University of Pennsylvania / Warren Pear, M.D., Ph.D., | Innovation Grants | 2014 | Pennsylvania |
| Correction of Hematopoietic Defects in Down Syndrome by Chromosome 21 Silencing | University of Massachusetts Medical School / Peter Newburger, M.D. | Innovation Grants | 2014 | Massachusetts |
| Role of LMO1 in Neuroblastoma Initiation and Maintenance: Analysis in the Zebrafish model of Childhood Neuroblastoma | Dana-Farber Cancer Institute / Thomas Look, M.D. | Innovation Grants | 2014 | Massachusetts |
| Identifying Drug Resistant Mutations in Ph-like Acute Lymphoblastic Leukemia | University of California San Francisco / Mignon Loh, M.D. | Innovation Grants | 2014 | California |
| Mechanisms of LGR5 Regulation and Function in Ewing sarcoma Metastasis | University of Michigan / Elizabeth Lawlor, M.D., Ph.D. | Innovation Grants | 2014 | Michigan |
| Modeling the Multi-hit Pathogenesis of t(12;21) Associated Pediatric ALL by CRISPR/Cas-mediated Genome Engineering | Massachusetts General Hospital / Hanno Hock, M.D., Ph.D. | Innovation Grants | 2014 | Massachusetts |
| Developing Personalized (precision) Medicine Strategies to Optimize Pediatric Brain Tumor Management | Washington University / David Gutmann, M.D., Ph.D. | Innovation Grants | 2014 | Missouri |
| Two-pronged Cell Therapy: Engineering T Cells to Redirect Bystander T- and NK-Cells to Pediatric Cancer | Baylor College of Medicine / Stephen Gottschalk, M.D. | Innovation Grants | 2014 | Texas |
| Development of AAV Vectors for Efficient Targeting and Elimination of Osteosarcoma Tumor-Initiating Cells | University of Florida / Steven Ghivizzani, Ph.D. | Innovation Grants | 2014 | Florida |
| Targeting MYC/MYCN-driven Transcriptional Amplification in Pediatric Cancer | Dana-Farber Cancer Institute / Rani George, M.D., Ph.D. | Innovation Grants | 2014 | Massachusetts |
| Converting the Glioblastoma Multiforme Tumor-Associated Macrophage Phenotype | The Johns Hopkins University School of Medicine / Alan D. Friedman, M.D. | Innovation Grants | 2014 | Maryland |
| Targeting the Six1/Eya Transcriptional Complex to Inhibit Pediatric Sarcomas | University of Colorado Denver / Heide Ford, Ph.D. | Innovation Grants | 2014 | Colorado |
| Mechanisms and Targeted Inhibition of NT5C2 Mutations in Relapsed ALL | Columbia University / Adolfo A. Ferrando, M.D., Ph.D. | Innovation Grants | 2014 | New York |
| Exploiting Epigenetic Dependencies of Notch1 for Clinical Benefit | University of Colorado Denver / Patricia Ernst, Ph.D. | Innovation Grants | 2014 | Colorado |
| Development of Targeted Leukemia Inhibitors Using Nanoparticle Delivery | University of Massachusetts Medical School / Lucio Castilla, Ph.D. | Innovation Grants | 2014 | Massachusetts |
| Genetic Alterations in Intramedullary Spinal Cord Tumors | The Johns Hopkins University School of Medicine / George Jallo, MD | Innovation Grants | 2013 | Maryland |
| Development of MicroRNA-Nanoparticles to Treat Childhood Acute Leukemia Carrying MLL Rearrangements | University of Cincinnati College of Medicine / Jianjun Chen, PhD | Innovation Grants | 2013 | Ohio |
| Engager T cells for the Adoptive Immunotherapy of Pediatric Malignancies | Baylor College of Medicine / Stephen Gottschalk, MD | Innovation Grants | 2013 | Texas |
| Multispecific T Cells for Adoptive Immunotherapy of Pediatric High Grade Glioma (HGG) | Baylor College of Medicine / Nabil Ahmed, MD, MSc | Innovation Grants | 2013 | Texas |
| An Intersection of Cell Metabolism and Differentiation in Childhood Sarcomas | Cedars-Sinai Medical Center / Sandra Orsulic, PhD | Innovation Grants | 2013 | California |
| Novel Targeted Therapies for Rhabdomyosarcoma | St. Jude Children’s Research Hospital / Michael Dyer, PhD | Innovation Grants | 2013 | Tennessee |
| Defining the Role of a Novel, Developmentally Restricted Hematopoietic Stem Cell in Pediatric Leukemias | University of California at Santa Cruz / Camilla Forsberg, PhD | Innovation Grants | 2013 | California |
| Therapeutic Potential of the MST1/Hippo Tumor Suppressor Pathway in Alveolar Rhabdomyosarcoma | Duke University / Corinne Mary Linardic, MD, PhD | Innovation Grants | 2013 | North Carolina |
| Identification of TFAP4 (Transcription Factor AP-4/Activating Enhancer Binding Protein) as a Potential Master Regulator/Synthetic Lethal Gene of MYCN Amplified Neuroblastoma | Columbia University Medical Center / Darrell Yamashiro, MD, PhD | Innovation Grants | 2013 | New York |
| Reactivating Apoptosis in Refractory Pediatric Cancer by Molecular Inhibition of MCL-1 | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD | Innovation Grants | 2013 | Massachusetts |
| Therapeutically Targeting a Tumor Suppressor Complex in Aggressive Pediatric Cancers | Dana-Farber Cancer Institute / Charles Roberts, MD, PhD | Innovation Grants | 2013 | Massachusetts |
| Epigenetic Characterization of the Neuroblastoma Driver Genes ARID1A and ARID1B | Children’s Hospital of Philadelphia / Michael Hogarty, MD | Innovation Grants | 2013 | Pennsylvania |
| Next-Generation Therapies for Hedgehog Pathway-Dependent Tumors | Lucile Packard Children’s Hospital at Stanford University School of Medicine / James Chen, PhD | Innovation Grants | 2013 | California |
| Pre-Clinical Testing of T cells Coded with CARs for DIPG | University of Texas / Laurence Cooper, MD, PhD | Innovation Grants | 2013 | Texas |
| Mechanisms Regulating Medulloblastoma Progression | University of Pennsylvania / Nadia Dahmane, PhD | Innovation Grants | 2013 | Pennsylvania |
| Novel Therapeutic Targets in Relapse T-cell Acute Lymphoblastic Leukemia | Massachusetts General Hospital / David Langenau, PhD | Innovation Grants | 2013 | Massachusetts |
| Therapeutic Targeting of LARG-RhoA Signaling Axis in Childhood Leukemia | Cincinnati Children's Hospital Medical Center / Yi Zheng, PhD | Innovation Grants | 2013 | Ohio |
| DICER1, MicroRNAs and Pediatric Cancer: An Emerging Story | Research Institute of the McGill University Health Centre / William Foulkes, MD, PhD | Innovation Grants | 2013 | Quebec |
| An Oncolytic Herpes Simplex Virus Restricted in Entry to Neuroblastoma Cells | Northwestern University Medical School / Richard Longnecker, PhD | Innovation Grants | 2013 | Illinois |
| Nanoparticle Delivery of Therapeutic Agents in Neuroblastomas | Children’s Hospital of Philadelphia / Garrett M. Brodeur, MD | Innovation Grants | 2013 | Pennsylvania |
| In-UTR mutations in neuroblastoma: Functional consequences and therapeutic implications | Children’s Hospital of Philadelphia / Andrei Thomas-Tikhonenko, PhD | Innovation Grants | 2012 | Pennsylvania |
| Targeting Neovascularization in Graft-Versus-Host Disease | Memorial Sloan-Kettering Cancer Center / Marcel van den Brink, MD/PhD | Innovation Grants | 2012 | New York |
| Modeling Pediatric Leukemia in the Zebrafish to Enable Discovery of New Anti-Leukemic Compounds | University of California, San Diego / David Traver, MD | Innovation Grants | 2012 | California |
| Identification and validation of new therapeutic targets in pediatric leukemia through an aneuploidy-based synthetic lethality screen | Dana-Farber Cancer Institute / David Pellman, MD | Innovation Grants | 2012 | Massachusetts |
| Identification of predisposition genes for Ewing sarcoma segregating in high-risk pedigrees | Huntsman Cancer Institute / Lisa Cannon-Albright, PhD | Innovation Grants | 2012 | Utah |
| A novel mouse model of rhabdomyosarcoma | Vanderbilt University Medical Center / Chin Chiang, PhD | Innovation Grants | 2012 | Tennessee |
| Casein Kinase 1 alpha Agonists as Novel Medulloblastoma Inhibitors | University of Miami Miller School of Medicine / David Robbins, PhD | Innovation Grants | 2012 | Florida |
| V alpha-invariant NKT cells as a novel platform for cancer immunotherapy | Baylor College of Medicine / Leonid Metelitsa, MD, PhD | Innovation Grants | 2012 | Texas |
| Mechanisms of LYL1-associated T-ALL development | Baylor College of Medicine / Margaret Goodell, PhD | Innovation Grants | 2012 | Texas |
| Novel STAT3 drug development for childhood osteosarcoma therapy using drug repositioning | Research Institute at Nationwide Children's Hospital / Jiayuh Lin, PhD | Innovation Grants | 2012 | Ohio |
| Developing Immune-modulatory Strategies Against Primary and Metastatic Tumors in the Central Nervous System | Case Western Reserve University / Alex Huang, MD, PhD | Innovation Grants | 2012 | Ohio |
| Searching for genetic vulnerabilities in osteosarcoma through genome-wide RNAi screening | Dana-Farber Cancer Institute / Stuart Orkin, MD | Innovation Grants | 2012 | Massachusetts |
| The role of vitamin D in hepatoblastoma formation and prevention | Brigham and Women's Hospital / Wolfram Goessling, MD/PhD | Innovation Grants | 2012 | Massachusetts |
| Development of the Next Generation FLT3 Inhibitors for Pediatric AML and Infant ALL | The Johns Hopkins University School of Medicine / Donald Small, MD, PhD | Innovation Grants | 2012 | Maryland |
| BH3 Profiling to define therapy resistance classes in neuroblastoma | Children’s Hospital of Philadelphia / Michael Hogarty, MD | Innovation Grants | 2011 | Pennsylvania |
| Modeling Anaplastic Medulloblastoma using Cerebellar Stem Cells | Sanford-Burnham Medical Research Institute / Robert Wechsler-Reya, PhD | Innovation Grants | 2011 | California |
| Clinical Development of RNA Nanoparticle Vaccines Targeting Recurrent Pediatric Brain Cancers | Duke University / Duane Mitchell, MD, PhD | Innovation Grants | 2011 | North Carolina |
| Strategies for Epigenetically Reprogramming Neuroblastoma Cancer Stem Cells | Baylor College of Medicine / Jason Shohet, MD, PhD | Innovation Grants | 2011 | Texas |
| Predicting Outcome and Ameliorating Toxicities of the Immunotherapy of Neuroblastoma | University of California, San Diego / Alice Yu, MD, PhD | Innovation Grants | 2011 | California |
| Studying the clonal dynamics and evolution of leukemia using molecular barcodes | Lucile Packard Children’s Hospital at Stanford University School of Medicine / Matthew Porteus, MD, PhD | Innovation Grants | 2011 | California |
| Targeting inhibitory phosphatase signaling in high-risk childhood ALL | University of California San Francisco / Markus Muschen, MD, PhD | Innovation Grants | 2011 | California |
| The role of primary cilia in rhabdomyosarcoma | New York University School of Medicine / Brian Dynlacht, PhD | Innovation Grants | 2011 | New York |
| Blockade of MYCN in neuroblastoma | University of California San Francisco / William Weiss, MD/PhD | Innovation Grants | 2011 | California |
| Racial and Ethnic Disparities in Survival of Children with Neuroblastoma | University of Chicago / Susan Cohn, MD | Innovation Grants | 2011 | Illinois |
| Investigating the Role of Lin-28 in Germ Cell Tumorigenesis | Boston Children’s Hospital / George Daley, MD/PhD | Innovation Grants | 2011 | Massachusetts |
| In vivo Analysis of Neuroblastoma Pathogenesis using Transgenic Zebrafish | Dana-Farber Cancer Institute / Alfred Tom Look, MD | Innovation Grants | 2011 | Massachusetts |
| Treating Brain Tumor by Changing Cell Division Pattern | Yale School of Medicine / Weimin Zhong | Innovation Grants | 2010 | Connecticut |
| Elucidating the Initiation Mechanism of the Fanconi Anemia Pathway of DNA Damage Repair | Yale School of Medicine / Yong Xiong | Innovation Grants | 2010 | Connecticut |
| Targeting Neovascularization in Graft-Versus-Host Disease | Memorial Sloan-Kettering Cancer Center / Marcel van den Brink | Innovation Grants | 2010 | New York |
| Modeling Pediatric Leukemia in Zebra Fish to Enable Discovery of New Anti- Leukemic Compounds | University of California, San Diego / David Traver, MD | Innovation Grants | 2010 | California |
| In-UTR Mutations in Neuroblastoma: Functional Consequences and Therapeutic Implications | Children’s Hospital of Philadelphia / Andrei Thomas-Tikhonenko | Innovation Grants | 2010 | Pennsylvania |
| Identification of the Molecular Targets of MLL Translocation-Based Childhood Leukemia | Stowers Institute for Medical Research / Ali Shilatifard | Innovation Grants | 2010 | Missouri |
| Predicting Outcome for Patients with Metastatic Neuroblastoma by Analysis of Bone Marrow and Blood for a Neuroblastoma Gene Expression Signature | Children’s Hospital Los Angeles / Robert Seeger | Innovation Grants | 2010 | California |
| Identification of New Therapeutic Targets in Pediatric Acute Lymphoblastic Leukemia Through Mosaic Trisomy and Aneuploidy-Based Synthetic Lethality Screens | Dana-Farber Cancer Institute / David Pellman | Innovation Grants | 2010 | Massachusetts |
| Discovery of Inhibitors of MLL Fusion Proteins as Targeted Therapies for Pediatric Acute Leukemia | Nemours Center for Childhood Cancer Research / Andrew Napper | Innovation Grants | 2010 | Delaware |
| Novel Therapeutic Target in Leukemia Stem Cells | Cincinnati Children's Hospital Medical Center / James Mulloy | Innovation Grants | 2010 | Ohio |
| Pathogenesis of T-cell Acute Lymphoblastic Leukemia from Myeloproliferative Disorder | Duke University / Motonari Kondo | Innovation Grants | 2010 | North Carolina |
| Understanding the Role of a Novel Hereditary Cancer Gene | University of Texas Health Science Center at San Antonio / Patricia Dahia | Innovation Grants | 2010 | Texas |
| A novel compound for treatment of T cell leukemia | Huntsman Cancer Institute / Nikolaus Trede | Innovation Grants | 2010 | Utah |
| Targeting wnt in synovial sarcoma models. | Vanderbilt University Medical Center / Josiane Eid | Innovation Grants | 2009 | Tennessee |
| Adaptation of acute lymphoblastic leukemia (ALL) to the post-transplant allogeneic environment. | University of Rochester / Craig Mullen | Innovation Grants | 2009 | New York |
| BH3 profiling to define therapy resistance classes in neuroblastoma. | Children’s Hospital of Philadelphia / Michael Hogarty | Innovation Grants | 2009 | Pennsylvania |
| Pharmacogenomics of childhood AML susceptibility and treatment response. | Children’s Hospital of Philadelphia / Richard Aplenc | Innovation Grants | 2009 | Pennsylvania |
| Linking mitogenic sonic hedgehog signaling to the oncogene Yap 1 in neural stem/progenitor cells and medulloblastoma. | Memorial Sloan-Kettering Cancer Center / Anna Kenney, PhD | Innovation Grants | 2009 | New York |
| Molecular diagnostic, prognostic, and therapeutic approaches toward Ewing sarcoma. | Huntsman Cancer Institute / Stephen Lessnick | Innovation Grants | 2009 | Utah |
| Targeted regulation of acetylation as novel therapy for Ewing sarcoma. | Georgetown University / Jeffrey Toretsky | Innovation Grants | 2009 | District of Columbia |
| Modeling anaplastic medulloblastoma using cerebellar stem cells | Duke University / Robert Wechsler-Reya, PhD | Innovation Grants | 2009 | North Carolina |
| Metabolic control of p53 activation in T-ALL. | Duke University / Jeffrey Rathmell | Innovation Grants | 2009 | North Carolina |
| Epigenetic manipulation of leukemia. | Cincinnati Children's Hospital Medical Center / H. Leighton Grimes | Innovation Grants | 2009 | Ohio |
| Investigating the role of lin-28 in germ cell tumorigenesis | Boston Children’s Hospital / George Daley | Innovation Grants | 2009 | Massachusetts |
| Parallel sequencing to identify the causes of childhood cancer | Baylor College of Medicine / Sharon Plon | Innovation Grants | 2008 | Texas |
| Molecular Regulation of CNS Involvement in Pediatric ALL | New York University School of Medicine / Iannis Aifantis, PhD | Innovation Grants | 2008 | New York |
| PI-3 kinase as a novel and attractive target in pediatric cancer and neuroblastoma | Emory University / Donald Durden | Innovation Grants | 2008 | Georgia |
| Preclinical Studies of Gli1 Inhibition in Ewing Family Tumors | Children’s Hospital Los Angeles / William May | Innovation Grants | 2008 | California |
| HMG-I/Y in Pediatric Leukemia and Lymphoma | The Johns Hopkins University School of Medicine / Linda Smith Resar, MD | Innovation Grants | 2008 | Maryland |
| The role of OCT4 in self-renewal signaling and drug-resistance of childhood acute lymphoblastic leukemia | Children’s Hospital Los Angeles / Markus Muschen | Innovation Grants | 2008 | California |
| Inhibition of Cathepsins to Treat Neuroblastoma | Alfred I duPont Hospital for Children / Robert Mason | Innovation Grants | 2008 | Delaware |
| Generation of CHD5 Antibodies and Know-out Mouse Model | Children’s Hospital of Philadelphia / Garrett Brodeur | Innovation Grants | 2008 | Pennsylvania |
| Therapeutics In Ovo | Oregon Health & Science University / Charles Keller | Innovation Grants | 2008 | Oregon |
| Blockade of Mycn in neuroblastoma | University of California San Francisco / William Weiss | Innovation Grants | 2008 | California |
| The role of immunogenetics in natural killer cell targeting of neuroblastoma | Memorial Sloan-Kettering Cancer Center / Katharine Hsu | Innovation Grants | 2008 | New York |
| TrkB Signaling in the Genesis of Murine Neuroblastoma | University of Vermont / Rae Nishi, PhD | Innovation Grants | 2007 | Vermont |
| Establishing surrogate markers of angiogenesis in pediatric oncology phase I and II clinical trials: A Children’s Oncology Group study | Hospital for Sick Children / Sylvain Baruchel, MD | Innovation Grants | 2007 | Ontario |
| The role of overexpressed microRNA’s in the pediatric cancer rhabdomyosarcoma | University of Pennsylvania / Frederic Barr, MD, PhD | Innovation Grants | 2007 | Pennsylvania |
| Rac in p190-BCR-ABL0Induced Leukemia. | Cincinnati Children's Hospital Medical Center / Jose Cancelas, MD, PhD | Innovation Grants | 2007 | Ohio |
| Adoptive immunotherapy using clinical-grade T cells. | University of Texas M.D. Anderson Cancer Center / Laurence Cooper, MD, PhD | Innovation Grants | 2007 | Texas |
| Tumor cell hybridoma vaccine for recurrent neuroblastoma and Ewing sarcoma | The Pennsylvania State University / Ken Lucas, MD | Innovation Grants | 2006 | Pennsylvania |
| Tyrosine Kinase Mutation Discovery in Neuroblastoma. | Dana-Farber Cancer Institute / Matthew Meyerson, MD, PhD | Innovation Grants | 2006 | Massachusetts |
| Molecular characterization of OTX2 as a novel therapeutic target. | Duke University Medical Center / Hai Yan, MD | Innovation Grants | 2006 | North Carolina |
| Parallel sequencing to identify the causes of childhood cancer. | Baylor College of Medicine / Sharon Plon, MD, PhD | Innovation Grants | 2006 | Texas |
| HMG-I/Y in pediatric Leukemia and Lymphoma. | The Johns Hopkins University School of Medicine / Linda Smith Resar, MD | Innovation Grants | 2006 | Maryland |
| Targeting Pediatric Brainstem Glioma with Oncolytic Polioviruses. | Duke University Medical Center / Matthias Gromeier, MD | Innovation Grants | 2006 | North Carolina |
| Anti-Angiogenic (Metronomic) Chemotherapy in Children with Poor Prognosis. | Dana-Farber Cancer Institute / Mark Kieran, MD, PhD | Innovation Grants | 2006 | Massachusetts |